Avraham Pharmaceuticals For Profit
Avraham Pharmaceuticals (“Avraham”) is a privately held, emerging pharmaceutical company developing novel products for treatment and/or prevention of neurodegenerative disorders. Founded in 2010, Avraham has raised $9 million to conduct a European Phase II proof-of-concept efficacy trial in patients with Alzheimer's disease, supporting the development of its lead product candidate, ladostigil.
Technology:
Neuropharmacology
Estimated Revenue:
$5 million
Employee Number:
11-50
Investment Stage:
N/A
Industry:
NeuroTech
Founded Date:
2010-01-01
Headquarters:
Yavneh, HaMerkaz, Israel
Number Of Exists:
N/A
Investor Type:
N/A
Funding Status:
N/A